Product Description
a panRAF InhibitorÊfor Patients With Advanced Solid Tumours, Including Metastatic Melanoma (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02437227)
Mechanisms of Action: RAFk Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Royal Marsden NHS Foundation Trust
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Melanoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02437227 |
PanRAF | P1 |
Completed |
Melanoma |
2017-12-01 |
2019-06-13 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|